Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Elicio Therapeutics (ELTX) Accumulated Depreciation & Amortization (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Accumulated Depreciation & Amortization readings, the most recent being $1.2 million for Q4 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 9.62% to $1.2 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.2 million, a 9.62% increase, with the full-year FY2023 number at $1.2 million, up 9.62% from a year prior.
  • Accumulated Depreciation & Amortization hit $1.2 million in Q4 2023 for Elicio Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.4 million in Q3 2023 to a low of $426000.0 in Q4 2020.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $564500.0 (2022), compared with a mean of $758000.0.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 117.21% in 2022 and later rose 9.62% in 2023.
  • Elicio Therapeutics' Accumulated Depreciation & Amortization stood at $426000.0 in 2020, then rose by 21.36% to $517000.0 in 2021, then skyrocketed by 117.21% to $1.1 million in 2022, then grew by 9.62% to $1.2 million in 2023.
  • The last three reported values for Accumulated Depreciation & Amortization were $1.2 million (Q4 2023), $1.4 million (Q3 2023), and $1.2 million (Q2 2023) per Business Quant data.